Session: 602. Myeloid Oncogenesis: Basic: Poster II
Hematology Disease Topics & Pathways:
AML, Acute Myeloid Malignancies, Research, Translational Research, Hematopoiesis, Diseases, Myeloid Malignancies, Biological Processes
Methods and Results. (i) The deubiquitinase USP7 is a key component of the ubiquitin-proteosome pathway (UPP) and is known to regulate p53 proteolysis in cell contexts other than myeloid. To evaluate a potential role for USP7 in regulating p53 in FLT3-ITD AML cells (MOLM13), we immunoprecipitated endogenous USP7 and used liquid chromatography tandem mass spectrometry (IP-LCMS/MS) to analyze for post-translational modifications in presence/absence of FLT3-ITD kinase-inhibitors: USP7 was phosphorylated at serine-18 (S18-P), a highly conserved residue. Kinase-inhibition decreased S18-P by ~50%, increased USP7 and p53 protein (Western blot, WB), and activated apoptosis in FLT3-ITD (MOLM13, MV4-11) but not FLT3-wildtype (WT) (THP1, OCI-AML3) AML cells (annexin/PI staining).
(ii) The small molecule P22077 is a specific modifier of the catalytic site in USP7 but not other deubiquitinases (Pozhidaeva. Cell Chem Biol 2017;24(12):1501). P22077 2.5 µM increased p53 protein (WB), and activated apoptosis (annexin/PI staining), again in FLT3-ITD but not FLT3-WT AML cells.
(iii) We reasoned that if FLT3-ITD signaling continuously degrades p53, then inhibiting the proteosome should also increase p53, without need for kinase-inhibitors. Bortezomib to inhibit the 26S proteasome increased p53 and activated apoptosis specifically in FLT3-ITD but not FLT3-WT AML cells, results reproduced with MG-132 that inhibits the 20S proteosome.
(iv) Consistent with FLT3-ITD acting as an alternative to TP53 genetic alterations to suppress p53, FLT3-ITD and TP53 mutations or deletions were mutually exclusive, although all are highly recurrent (analyses of TCGA data).
(v) IP-LCMS/MS of endogenous USP7 revealed interactions also with CEBPA, the master transcription factor driver of granulocytic differentiation. USP7/CEBPA interactions were confirmed by reverse IP-LCMS/MS of endogenous CEBPA, and by bi-directional IP-WB of endogenous USP7 and CEBPA. Demonstrating functional significance, FLT3-ITD AML cells (MOLM13, MV4-11) contained high CEBPA mRNA but little CEBPA protein. Inhibiting FLT3-ITD signaling increased total CEBPA protein even as CEBPA S21-P decreased, and activated granulocytic differentiation (in addition to apoptosis). Further supporting that CEBPA S21-P is a degron, broad-spectrum proteosome inhibitors increased S21-P and total CEBPA protein. Extending these results beyond cell lines, FLT3-ITD and FLT3-wildtype (WT) primary AML cells expressed similar amounts of CEBPA mRNA, but CEBPA target-genes were ~2-fold suppressed in FLT3-ITD (n=27) vs FLT3-WT (n=90) cells, with a significant positive correlation between CEBPA and CEBPA target-gene activation in FLT3-WT but not FLT3-ITD cells. Consistent with FLT3 and CEBPA operating in the same pathway, FLT3-ITD was mutually exclusive with biallelic CEBPA mutations (analyses of TCGA data).
Results in Context. Normal FLT3 signaling expands granulo-monocytic progenitors. Thus, FLT3-ITD promotion of p53 and CEBPA proteolysis may represent continuous imposition of molecular actions that are normally ligand-activated and transient. These mechanisms support evaluation of proteosome inhibitors, approved for other indications, as candidate treatments for relapsed/refractory FLT3-ITD AMLs, supported also by other reports of specific sensitivity of FLT3-ITD AML cells to proteosome inhibitors (Larrue. Blood 2016;127(7):882. Long. Cell Rpts Med 2023;4(11):101286). Presently, midostaurin to inhibit FLT3-ITD signaling is ingested on days after infusional chemotherapy - the mechanisms shown here suggest ingestion simultaneous or immediately-after chemotherapy, so that p53 is more available to respond to chemotherapy stress and activate apoptosis – timings again supported by in vitro studies by others (Levis. Blood 2004;104(4):1145. Schittenhelm. Cell cycle 2009;8(16):2621).
Disclosures: Saunthararajah: University of Illinois: Patents & Royalties; EpiDestiny: Consultancy, Current equity holder in private company; Treebough: Current equity holder in private company.